PTC Therapeutics, Inc. (PTCT)
NEUTRALFondamental
58
Prix
$72.81
Capitalisation boursière
$5.77B
Partie 1 · Ce que vaut l'entreprise
Vue d'ensemble
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilan & Liquidités
Chiffre d'affaires
$1.01B
12 derniers mois (au 30/06/2026)
Résultat net
$-38M
12 derniers mois (au 30/06/2026)
Flux de trésorerie libre
$702M
Capitaux propres totaux
$-205M
Passif total
$3.10B
Ratio de liquidité général
3.39
Couverture des intérêts
-
Dette/EBITDA
0.77
Bénéfice par action
Chiffre d'affaires & Résultat net
Flux de trésorerie libre
Décomposition du résultat
État historique
Marges dans le temps
La dette dans le temps
Le poids de la dette
Grille de la croissance
Croissance — Chiffre d'affaires
Estimation de la juste valeur
Juste valeur
$150.93
Prix actuel
$72.81
Marge de sécurité
+51.8%
Fourchette de juste valeur
$98.10 - $203.75
Méthodes d'estimation
Indicateurs de valorisation
Ratio P/E
8.89
ROE
-332.5%
Ratio P/B
-
P/FCF
8.22
Marge brute
-
ROIC
4.0%
Radar de rentabilité
Value Creation (Economic Moat)
ROIC
4.0%
WACC
7.2%
ROIC − WACC
-3.2 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Critères d'analyse fondamentale
Réussi (10)
- EPS shows upward trend
- Price CAGR 20.40%
- P/FCF 8.22
- Operating Margin 12.5%
- Current Ratio
- Debt/EBITDA
- DCF valuation (Undervalued)
- Revenue Growth 5Y 135.4%
- Analyst Consensus 81% Buy
- Piotroski F-Score 6/9
Échoué (9)
- EPS CAGR 3.91%
- ROIC 4.0%
- Positive Free Cash Flow
- Return on Tangible Assets
- Low reliance on intangibles
- ROE -351.9%
- Earnings Surprise avg -1034.0%
- Share Dilution 14.2%
- Net Margin Trend -3.8% vs 35.6%
Indisponible (9)
- Gross Margin NaN%
- P/B Ratio NaN
- Dividend Payout NaN%
- Debt/Equity ratio
- CapEx intensity
- Interest Coverage
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Score F de Piotroski
Signaux mixtes : certains domaines nécessitent attention
Qualité des bénéfices
Qualité faible : examiner la comptabilité
Dilution du capital
Émission de nouvelles actions, diluant la participation
Gouvernance
Équipe dirigeante
| Nom | Titre | Âge |
|---|---|---|
| Dr. Matthew B. Klein F.A.C.S., M.D., M.S. | CEO & Director | 53 |
| Dr. Allan Steven Jacobson Ph.D. | Co-Founder & Independent Director | 79 |
| Mr. Pierre Gravier M.S. | Chief Financial Officer | 40 |
| Dr. Neil Almstead Ph.D. | Chief Technical Operations Officer | 58 |
| Mr. Eric Pauwels | Chief Business Officer | 63 |
| Dr. Lee Scott Golden M.D., Ph.D. | Executive VP & Chief Medical Officer | 57 |
| Ms. Christine Utter CPA | Senior VP, Chief Accounting Officer & Head of People Services | 46 |
| Ms. Linda Montella Carter | Senior VP & Chief Information Officer | - |
| Ms. Ellen Cavaleri | Head of Investor Relations | - |
| Mr. Mark Elliott Boulding J.D. | Executive VP & Chief Legal Officer | 64 |
Risque d'audit
3
Risque du conseil
3
Risque de rémunération
4
Risque droits des actionnaires
7
Partie 2 · Le prix et le moment d'entrer
Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.
Latest News
Recent headlines for PTCT, sourced from Markets Gazette.
- 3/3/2026POSITIVEInvestment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing
Investor confidence in PTC Therapeutics (PTCT) appears to be on the rise, following a recent SEC filing that disclosed a significant purchase of 41,000 shares by an investment manager. This strategic move suggests a positive outlook on the future of the company, which specializes in developing therapies for rare diseases. The increased stake by an institutional player can be interpreted as a bullish signal, indicating that the market might be underestimating the potential of PTC Therapeutics' portfolio of commercial products and investigational candidates. Investors should closely monitor the stock's performance, as such an endorsement often precedes positive price movements, reflecting stronger conviction in the company's business model and long-term growth prospects within the biopharmaceutical sector.
via Markets Gazette